Voronoi Co. Ltd.
Voronoi, Inc. researches, develops, and discovers small molecule kinase inhibitors in South Korea. Its products pipeline includes VRN01, an oral leucine rich repeat kinase 2 inhibitor targeting glioblastoma multiforme to treat brain and pancreatic cancers; VRN07, VRN06, and VRN11 for the treatment of lung cancer; VRN08 and VRN10 to treat breast cancer; and VRN02 for the treatment of rheumatoid ar… Read more
Voronoi Co. Ltd. (310210) - Total Liabilities
Latest total liabilities as of September 2025: ₩46.35 Billion KRW
Based on the latest financial reports, Voronoi Co. Ltd. (310210) has total liabilities worth ₩46.35 Billion KRW as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Voronoi Co. Ltd. - Total Liabilities Trend (2019–2024)
This chart illustrates how Voronoi Co. Ltd.'s total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Voronoi Co. Ltd. Competitors by Total Liabilities
The table below lists competitors of Voronoi Co. Ltd. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Engie Brasil Energia SA
PINK:EGIEY
|
USA | $41.38 Billion |
|
Dana Inc
NYSE:DAN
|
USA | $6.89 Billion |
|
First Capital Real Estate Investment Trust
PINK:FCXXF
|
USA | $4.34 Billion |
|
Bangkok Expressway and Metro Public Company Limited
PINK:BKKXF
|
USA | $114.55 Billion |
|
SOCNF
PINK:SOCNF
|
USA | $38.16 Billion |
|
The Unite Group plc
F:U1B
|
Germany | €1.55 Billion |
|
BancFirst Corporation
NASDAQ:BANF
|
USA | $8.67 Billion |
|
Privia Health Group Inc
NASDAQ:PRVA
|
USA | $578.43 Billion |
Liability Composition Analysis (2019–2024)
This chart breaks down Voronoi Co. Ltd.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 15.73 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.87 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.47 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Voronoi Co. Ltd.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Voronoi Co. Ltd. (2019–2024)
The table below shows the annual total liabilities of Voronoi Co. Ltd. from 2019 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | ₩7.25 Billion | -45.56% |
| 2023-12-31 | ₩13.31 Billion | -55.17% |
| 2022-12-31 | ₩29.69 Billion | -10.68% |
| 2021-12-31 | ₩33.24 Billion | +69.47% |
| 2020-12-31 | ₩19.62 Billion | +16.80% |
| 2019-12-31 | ₩16.79 Billion | -- |